Alex­ion shelves an ear­ly-stage San­fil­ip­po B drug, writes off $85M

When Alex­ion bought out Synage­va in an $8.4 bil­lion deal a lit­tle less than two years ago, the big at­trac­tion was Kanu­ma, a rare dis­ease drug that went on to an ap­proval. But there was one no­table pipeline ther­a­py, SBC-103 for rare cas­es of San­fil­ip­po B, that drew some at­ten­tion for the val­u­a­tion.

Un­til to­day. Alex­ion said in its 2016 re­view that it is stop­ping work on SBC-103, a re­com­bi­nant form of the NAGLU en­zyme, tak­ing an $85 mil­lion write-off. Here’s the bur­ial an­nounce­ment:

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.